Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen
Shoichiro Tsuji, … , Jeffrey L. Platt, Marilia Cascalho
Shoichiro Tsuji, … , Jeffrey L. Platt, Marilia Cascalho
Published October 1, 2014
Citation Information: J Clin Invest. 2014;124(11):4857-4866. https://doi.org/10.1172/JCI74428.
View: Text | PDF
Research Article Immunology Article has an altmetric score of 1

TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen

  • Text
  • PDF
Abstract

The transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) controls differentiation of long-lived plasma cells, and almost 10% of individuals with common variable immunodeficiency (CVID) express either the C104R or A181E variants of TACI. These variants impair TACI function, and TACI-deficient mice exhibit a CVID-like disease. However, 1%–2% of normal individuals harbor the C140R or A181E TACI variants and have no outward signs of CVID, and it is not clear why TACI deficiency in this group does not cause disease. Here, we determined that TACI-deficient mice have low baseline levels of Ig in the blood but retain the ability to mutate Ig-associated genes that encode antigen-specific antibodies. The antigen-specific antibodies in TACI-deficient mice were produced in bursts and had higher avidity than those of WT animals. Moreover, mice lacking TACI were able to clear Citrobacter rodentium, a model pathogen for severe human enteritis, more rapidly than did WT mice. These findings suggest that the high prevalence of TACI deficiency in humans might reflect enhanced host defense against enteritis, which is more severe in those with acquired or inherited immunodeficiencies.

Authors

Shoichiro Tsuji, Lucas Stein, Nobuhiko Kamada, Gabriel Nuñez, Richard Bram, Bruce A. Vallance, Ana E. Sousa, Jeffrey L. Platt, Marilia Cascalho

×

Figure 3

Impact of TACI deficiency on B cell proliferation and apoptosis.

Options: View larger image (or click on image) Download as PowerPoint
Impact of TACI deficiency on B cell proliferation and apoptosis.
(A) Num...
(A) Number of proliferating GC B cells in WT and TACI-deficient mice at 7, 14, or 28 days after immunization with SRBCs. Percentages of BrdU+ GC cells (CD19+GL7+FAS+). TACI deficiency increased proliferation of GC cells 7 days after immunization (P = 0.0002, Holm-Sidak test). (B) Immunofluorescence analysis of GC cell apoptosis. Apoptotic cells were identified by TUNEL, labeled ends were detected with anti-BrdU antibodies (green, upper diagrams and red, lower diagrams), and cells were counterstained with DAPI. Lower diagrams show costaining with anti-GL7 mAbs (green). Results are representative of 6 distinct sections obtained from 2 WT mice and 3 TACI-deficient mice. Original magnification, ×200. (C) Enumeration of apoptotic TUNEL+ GC cells. Taci-KO mice had fewer TUNEL+ cells per GC (P = 0.0012, Mann-Whitney U test). (D) Impact of TACI ligand blockade on B cell apoptosis. WT or Taci-KO splenic B cells were cultured with anti-CD40 and IL-4 in the presence or absence of TACI-Fc to inhibit TACI signaling. After 48 hours, caspase 3+ cells were enumerated by FACS. TACI deficiency or impaired TACI function decreased apoptosis after B cell activation, (P < 0.05, Mann-Whitney U test). (E and F) Relative expression by qPCR of cellular inhibitor of apoptosis (cIap) by GC B cells (E) or Tfh cells (F) 14 days after immunization with SRBCs. Expression of cIap was quantified in cDNA by qPCR reactions using specific primers and SYBR Green incorporation (P < 0.05, Mann-Whitney U test).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 2 X users
58 readers on Mendeley
See more details